Durect Corp (DRRX) 2.19 $DRRX
DURECT Corporation Invites You to Join its First Quarter 2015 Earnings Conference Call
PR Newswire - 2 hrs 46 mins ago
In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, April 30, 2015 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
DRRX: 2.19 (+0.10)
Fatty Liver Disease Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Thu Apr 16, 10:30AM CDT
The report "Fatty Liver Disease - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Fatty Liver Disease. Fatty liver disease is characterized by increased accumulation of fat, especially triglycerides, in the liver cells. Many people with fatty liver disease experience no symptoms, especially in the early stage of the disease. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/fatty-liver-...eport.html .
RPTP: 10.56 (-0.17), GILD: 104.18 (-1.02), CNAT: 6.31 (-0.15), CCXI: 7.86 (-0.02), DRRX: 2.19 (+0.10), TBRA: (), NVS: 103.45 (-0.62)
Healthcare stock screen of the month: Price extended, poor fundamentals
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 12:05PM CDT
CRMD: 8.86 (-0.28), ADXS: 22.18 (+0.10), CYTX: 0.96 (-0.09), CNDO: 4.09 (-0.09), AMRN: 2.34 (-0.05), AVEO: 2.04 (+0.12), NVGN: 7.40 (-0.30), AXN: 1.77 (+0.01), NYMX: 1.32 (-0.08), DRRX: 2.19 (+0.10), RIGL: 4.24 (+0.07), CAPN: 6.99 (-0.29)
Isis And Durect Foray Into NASH; Durect Is The Better Bet
Clinically Sound Investor - at Seeking Alpha - Mon Apr 06, 7:23PM CDT
ISIS: 66.26 (-0.03), DRRX: 2.19 (+0.10)
Stock to Watch: Durect Up 6.9% (DRRX)
Comtex SmarTrend(R) - Mon Mar 30, 10:45AM CDT
Durect (NASDAQ
RRX) is one of today's best performing low-priced stocks, up 6.9% to $2.01 on 2.4x average daily volume. Durect has traded 1.8 million shares thus far today, vs. average volume of 746,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's 1.5%) and outperformed the S&P 500 (6.9% to the S&P's 1.1%) during today's trading.
DRRX: 2.19 (+0.10)
DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study
PR Newswire - Mon Mar 30, 7:30AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE) that may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It may also play an important role in protecting against acute kidney injury (AKI) and other types of acute organ injury.
DRRX: 2.19 (+0.10)
BUYINS.NET: DRRX SqueezeTrigger Price is $1.66. There is $720,129 That Short Sellers Still Need To Cover.
M2 - Fri Mar 27, 4:36AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Durect Corp (NASDAQ RRX) in real time and just received an alert that DRRX is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 419900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.66. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
DRRX: 2.19 (+0.10)
Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study
GlobeNewswire - Thu Mar 26, 8:00AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that dosing has begun in patients enrolled in its Relday(TM) multi-dose Phase 1b clinical study. Relday is a proprietary, long-acting, subcutaneously injected formulation of risperidone being investigated for the treatment of schizophrenia.
ZGNX: 1.63 (-0.02), DRRX: 2.19 (+0.10)
5 Stocks Insiders Love Right Now
at The Street - Wed Mar 25, 6:00AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
PN: 14.26 (+0.02), SSNC: 63.47 (+0.76), DRRX: 2.19 (+0.10), EPD: 33.35 (-0.29), JMBA: 16.11 (-0.14)
InsiderInsights.com Daily Round Up 3/20/15: DRRX, RWC, GEF.B, MRD
InsiderInsights - at Seeking Alpha - Sat Mar 21, 2:29AM CDT
NPBC: 10.75 (+0.05), HCOM: 26.80 (+0.05), DRII: 33.20 (-0.23), LGIH: 17.57 (+0.03), MRD: 19.19 (+0.06), STKL: 10.77 (-0.20), DRRX: 2.19 (+0.10), GOOG: 539.36 (+5.39), WSTC: 32.53 (-0.23), NLY: 10.27 (+0.02), PDVW: 50.06 (-0.21), GMED: 25.09 (-0.16), MHK: 182.02 (+2.39), NERV: 5.68 (+0.05), JAZZ: 186.13 (-0.41), RWC: 6.24 (+0.12), GOOGL: 549.18 (+6.26), ROST: 103.90 (+0.28)
Hot Stock: Durect, Shares Gain 5.2% (DRRX)
Comtex SmarTrend(R) - Wed Mar 11, 10:16AM CDT
Durect (NASDAQ RRX) is one of today's best performing low-priced stocks, up 5.2% to $1.73 on 1.0x average daily volume. Durect has traded 394,000 shares thus far today, vs. average volume of 381,000 shares per day. The stock has outperformed the Dow (5.2% to the Dow's 0.0%) and outperformed the S&P 500 (5.2% to the S&P's -0.0%) during today's trading.
DRRX: 2.19 (+0.10)
Chronic Pain Therapeutics Pipeline Review 2015 - 62 Companies & 138 Drug Profiles
M2 - Wed Mar 11, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/98dtzm/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Akron Molecules AG - Allergan, Inc. - arGEN-X BV - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - BCN Peptides, S.A. - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - DURECT Corporation - Egalet Corporation - Eli Lilly and Company - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/98...ronic_pain
BDSI: 9.26 (+0.12), ENDP: 94.09 (-1.09), LLY: 72.30 (+0.09), DRRX: 2.19 (+0.10), AGN: 240.22 (+2.88), JNJ: 100.43 (+0.13), ACAD: 38.55 (-0.20), EGLT: 10.34 (-0.27), AZN: 73.35 (+0.65), ABBV: 64.52 (+0.91), PTIE: 1.85 (+0.01)
InsiderInsights.com Daily Round Up 3/9/15: DRRX, FANG, AXDX, RDUS
InsiderInsights - at Seeking Alpha - Tue Mar 10, 6:34AM CDT
STR: 23.95 (unch), NLSN: 46.10 (+0.27), VOYA: 43.01 (+0.42), NOC: 162.08 (-0.41), ARI: 17.05 (-0.05), OPHT: 52.35 (+1.09), WETF: 21.04 (-0.52), EVI: 3.35 (-0.09), MLNK: 3.75 (unch), DRRX: 2.19 (+0.10), RDUS: 41.90 (-0.48), AXDX: 23.62 (+0.10), HLX: 16.75 (+0.16), FANG: 81.98 (-0.83), FOXF: 15.28 (-0.13), SYK: 96.45 (+1.74), EHTH: 11.44 (+0.07)
Nasdaq stocks posting largest volume increases
AP - Fri Mar 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ICEL: 16.47 (-0.02), GILT: 6.20 (-0.09), CLDN: 13.59 (-2.77), ITCI: 23.78 (-0.81), DRRX: 2.19 (+0.10), DRAD: 4.59 (+0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 11:45AM CST
SSH: 4.18 (+0.04), ONCY: 0.80 (unch), LTM: 71.60 (+0.17), LEDS: 0.88 (unch), CLDN: 13.59 (-2.77), AXN: 1.77 (+0.01), EXAS: 22.28 (+0.24), DRRX: 2.19 (+0.10), DRAD: 4.59 (+0.05), BLRX: 2.12 (unch), GENE: 4.88 (-0.05), OREX: 7.39 (+0.22), ICEL: 16.47 (-0.02), BORN: 1.23 (+0.01), DMD: 6.60 (+0.10), AVEO: 2.04 (+0.12), CALA: 12.93 (-1.06), MTL: 1.29 (-0.01), CKP: 11.03 (-0.05), ERII: 3.22 (+0.09)
DURECT's Endogenous Epigenomic Regulator DUR-928 - What You Need To Know
Jason Napodano, CFA - at Seeking Alpha - Thu Mar 05, 2:10PM CST
MNK: 122.95 (-2.22), ENDP: 94.09 (-1.09), TEVA: 63.01 (-1.15), DRRX: 2.19 (+0.10)
Durect ups revenues 27% in FY14
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:41AM CST
DRRX: 2.19 (+0.10)
DURECT Corporation Invites You to Join its First Quarter 2015 Earnings Conference Call
PR Newswire - 2 hrs 46 mins ago
In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, April 30, 2015 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
DRRX: 2.19 (+0.10)
Fatty Liver Disease Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Thu Apr 16, 10:30AM CDT
The report "Fatty Liver Disease - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Fatty Liver Disease. Fatty liver disease is characterized by increased accumulation of fat, especially triglycerides, in the liver cells. Many people with fatty liver disease experience no symptoms, especially in the early stage of the disease. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/fatty-liver-...eport.html .
RPTP: 10.56 (-0.17), GILD: 104.18 (-1.02), CNAT: 6.31 (-0.15), CCXI: 7.86 (-0.02), DRRX: 2.19 (+0.10), TBRA: (), NVS: 103.45 (-0.62)
Healthcare stock screen of the month: Price extended, poor fundamentals
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 12:05PM CDT
CRMD: 8.86 (-0.28), ADXS: 22.18 (+0.10), CYTX: 0.96 (-0.09), CNDO: 4.09 (-0.09), AMRN: 2.34 (-0.05), AVEO: 2.04 (+0.12), NVGN: 7.40 (-0.30), AXN: 1.77 (+0.01), NYMX: 1.32 (-0.08), DRRX: 2.19 (+0.10), RIGL: 4.24 (+0.07), CAPN: 6.99 (-0.29)
Isis And Durect Foray Into NASH; Durect Is The Better Bet
Clinically Sound Investor - at Seeking Alpha - Mon Apr 06, 7:23PM CDT
ISIS: 66.26 (-0.03), DRRX: 2.19 (+0.10)
Stock to Watch: Durect Up 6.9% (DRRX)
Comtex SmarTrend(R) - Mon Mar 30, 10:45AM CDT
Durect (NASDAQ
RRX) is one of today's best performing low-priced stocks, up 6.9% to $2.01 on 2.4x average daily volume. Durect has traded 1.8 million shares thus far today, vs. average volume of 746,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's 1.5%) and outperformed the S&P 500 (6.9% to the S&P's 1.1%) during today's trading. DRRX: 2.19 (+0.10)
DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study
PR Newswire - Mon Mar 30, 7:30AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE) that may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It may also play an important role in protecting against acute kidney injury (AKI) and other types of acute organ injury.
DRRX: 2.19 (+0.10)
BUYINS.NET: DRRX SqueezeTrigger Price is $1.66. There is $720,129 That Short Sellers Still Need To Cover.
M2 - Fri Mar 27, 4:36AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Durect Corp (NASDAQ
RRX) in real time and just received an alert that DRRX is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 419900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.66. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com . DRRX: 2.19 (+0.10)
Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study
GlobeNewswire - Thu Mar 26, 8:00AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that dosing has begun in patients enrolled in its Relday(TM) multi-dose Phase 1b clinical study. Relday is a proprietary, long-acting, subcutaneously injected formulation of risperidone being investigated for the treatment of schizophrenia.
ZGNX: 1.63 (-0.02), DRRX: 2.19 (+0.10)
5 Stocks Insiders Love Right Now
at The Street - Wed Mar 25, 6:00AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
PN: 14.26 (+0.02), SSNC: 63.47 (+0.76), DRRX: 2.19 (+0.10), EPD: 33.35 (-0.29), JMBA: 16.11 (-0.14)
InsiderInsights.com Daily Round Up 3/20/15: DRRX, RWC, GEF.B, MRD
InsiderInsights - at Seeking Alpha - Sat Mar 21, 2:29AM CDT
NPBC: 10.75 (+0.05), HCOM: 26.80 (+0.05), DRII: 33.20 (-0.23), LGIH: 17.57 (+0.03), MRD: 19.19 (+0.06), STKL: 10.77 (-0.20), DRRX: 2.19 (+0.10), GOOG: 539.36 (+5.39), WSTC: 32.53 (-0.23), NLY: 10.27 (+0.02), PDVW: 50.06 (-0.21), GMED: 25.09 (-0.16), MHK: 182.02 (+2.39), NERV: 5.68 (+0.05), JAZZ: 186.13 (-0.41), RWC: 6.24 (+0.12), GOOGL: 549.18 (+6.26), ROST: 103.90 (+0.28)
Hot Stock: Durect, Shares Gain 5.2% (DRRX)
Comtex SmarTrend(R) - Wed Mar 11, 10:16AM CDT
Durect (NASDAQ
RRX) is one of today's best performing low-priced stocks, up 5.2% to $1.73 on 1.0x average daily volume. Durect has traded 394,000 shares thus far today, vs. average volume of 381,000 shares per day. The stock has outperformed the Dow (5.2% to the Dow's 0.0%) and outperformed the S&P 500 (5.2% to the S&P's -0.0%) during today's trading. DRRX: 2.19 (+0.10)
Chronic Pain Therapeutics Pipeline Review 2015 - 62 Companies & 138 Drug Profiles
M2 - Wed Mar 11, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/98dtzm/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Akron Molecules AG - Allergan, Inc. - arGEN-X BV - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - BCN Peptides, S.A. - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - DURECT Corporation - Egalet Corporation - Eli Lilly and Company - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/98...ronic_pain
BDSI: 9.26 (+0.12), ENDP: 94.09 (-1.09), LLY: 72.30 (+0.09), DRRX: 2.19 (+0.10), AGN: 240.22 (+2.88), JNJ: 100.43 (+0.13), ACAD: 38.55 (-0.20), EGLT: 10.34 (-0.27), AZN: 73.35 (+0.65), ABBV: 64.52 (+0.91), PTIE: 1.85 (+0.01)
InsiderInsights.com Daily Round Up 3/9/15: DRRX, FANG, AXDX, RDUS
InsiderInsights - at Seeking Alpha - Tue Mar 10, 6:34AM CDT
STR: 23.95 (unch), NLSN: 46.10 (+0.27), VOYA: 43.01 (+0.42), NOC: 162.08 (-0.41), ARI: 17.05 (-0.05), OPHT: 52.35 (+1.09), WETF: 21.04 (-0.52), EVI: 3.35 (-0.09), MLNK: 3.75 (unch), DRRX: 2.19 (+0.10), RDUS: 41.90 (-0.48), AXDX: 23.62 (+0.10), HLX: 16.75 (+0.16), FANG: 81.98 (-0.83), FOXF: 15.28 (-0.13), SYK: 96.45 (+1.74), EHTH: 11.44 (+0.07)
Nasdaq stocks posting largest volume increases
AP - Fri Mar 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ICEL: 16.47 (-0.02), GILT: 6.20 (-0.09), CLDN: 13.59 (-2.77), ITCI: 23.78 (-0.81), DRRX: 2.19 (+0.10), DRAD: 4.59 (+0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 11:45AM CST
SSH: 4.18 (+0.04), ONCY: 0.80 (unch), LTM: 71.60 (+0.17), LEDS: 0.88 (unch), CLDN: 13.59 (-2.77), AXN: 1.77 (+0.01), EXAS: 22.28 (+0.24), DRRX: 2.19 (+0.10), DRAD: 4.59 (+0.05), BLRX: 2.12 (unch), GENE: 4.88 (-0.05), OREX: 7.39 (+0.22), ICEL: 16.47 (-0.02), BORN: 1.23 (+0.01), DMD: 6.60 (+0.10), AVEO: 2.04 (+0.12), CALA: 12.93 (-1.06), MTL: 1.29 (-0.01), CKP: 11.03 (-0.05), ERII: 3.22 (+0.09)
DURECT's Endogenous Epigenomic Regulator DUR-928 - What You Need To Know
Jason Napodano, CFA - at Seeking Alpha - Thu Mar 05, 2:10PM CST
MNK: 122.95 (-2.22), ENDP: 94.09 (-1.09), TEVA: 63.01 (-1.15), DRRX: 2.19 (+0.10)
Durect ups revenues 27% in FY14
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:41AM CST
DRRX: 2.19 (+0.10)
